FrancophonIA/ELRC3.0 huggingface dataset:
English: EU/2/15/191/011 (40 mg, 3 tablets) EU/2/15/191/012 (40 mg, 6 tablets) EU/2/15/191/013 (80 mg, 1 tablet) EU/2/15/191/014 (80 mg, 3 tablets) EU/2/15/191/015 (80 mg, 6 tablets) EU/2/15/191/016 (120 mg, 1 tablet) EU/2/15/191/017 (120 mg, 3 tablets) EU/2/15/191/018 (120 mg, 6 tablets)
Estonian: EU/2/15/191/008 (20 mg, 3 tabletti) EU/2/15/191/009 (20 mg, 6 tabletti) EU/2/15/191/010 (40 mg, 1 tablett) EU/2/15/191/011 (40 mg, 3 tabletti) EU/2/15/191/012 (40 mg, 6 tabletti) EU/2/15/191/013 (80 mg, 1 tablett) EU/2/15/191/014 (80 mg, 3 tabletti) EU/2/15/191/015 (80 mg, 6 tabletti) EU/2/15/191/016 (120 mg, 1 tablett) EU/2/15/191/017 (120 mg, 3 tabletti) EU/2/15/191/018 (120 mg, 6 tabletti)
English: PACKAGE LEAFLET: Simparica chewable tablets for dogs
Estonian: PAKENDI INFOLEHT Simparica närimistabletid koertele
English: EU/2/15/191/001 (5 mg, 1 tablet) EU/2/15/191/002 (5 mg, 3 tablets) EU/2/15/191/003 (5 mg, 6 tablets) EU/2/15/191/004 (10 mg, 1 tablet) EU/2/15/191/005 (10 mg, 3 tablets) EU/2/15/191/006 (10 mg, 6 tablets) EU/2/15/191/007 (20 mg, 1 tablet) EU/2/15/191/008 (20 mg, 3 tablets) EU/2/15/191/009 (20 mg, 6 tablets) EU/2/15/191/010 (40 mg, 1 tablet)
Estonian: EU/2/15/191/001 (5 mg, 1 tablett) EU/2/15/191/002 (5 mg, 3 tabletti) EU/2/15/191/003 (5 mg, 6 tabletti) EU/2/15/191/004 (10 mg, 1 tablett) EU/2/15/191/005 (10 mg, 3 tabletti) EU/2/15/191/006 (10 mg, 6 tabletti) EU/2/15/191/007 (20 mg, 1 tablett)
English: Each tablet contains: Simparica chewable tablets sarolaner (mg)
Estonian: Üks tablett sisaldab: Simparica närimistabletid sarolaneer (mg)
English: Simparica chewable tablets sarolaner (mg)
Estonian: Toimeaine: Simparica närimistabletid sarolaneer (mg)
English: Simparica 5 mg chewable tablets for dogs 1.3-2.5 kg Simparica 10 mg chewable tablets for dogs >2.5-5 kg Simparica 20 mg chewable tablets for dogs >5-10 kg Simparica 40 mg chewable tablets for dogs >10-20 kg Simparica 80 mg chewable tablets for dogs >20-40 kg Simparica 120 mg chewable tablets for dogs >40-60 kg sarolaner
Estonian: Simparica 5 mg närimistabletid koertele kehamassiga 1,3-2,5 kg Simparica 10 mg närimistabletid koertele kehamassiga > 2,5-5 kg Simparica 20 mg närimistabletid koertele kehamassiga > 5-10 kg Simparica 40 mg närimistabletid koertele kehamassiga > 10-20 kg Simparica 80 mg närimistabletid koertele kehamassiga > 20-40 kg Simparica 120 mg närimistabletid koertele kehamassiga > 40-60 kg sarolaneer
English: Simparica 5 mg chewable tablets for dogs 1.3-2.5 kg Simparica 10 mg chewable tablets for dogs >2.5-5 kg Simparica 20 mg chewable tablets for dogs >5-10 kg Simparica 40 mg chewable tablets for dogs >10-20 kg Simparica 80 mg chewable tablets for dogs >20-40 kg Simparica 120 mg chewable tablets for dogs >40-60 kg
Estonian: Simparica, 5 mg närimistabletid koertele kehamassiga 1,3-2,5 kg Simparica, 10 mg närimistabletid koertele kehamassiga > 2,5-5 kg Simparica, 20 mg närimistabletid koertele kehamassiga > 5-10 kg Simparica, 40 mg närimistabletid koertele kehamassiga > 10-20 kg Simparica, 80 mg närimistabletid koertele kehamassiga > 20-40 kg Simparica, 120 mg närimistabletid koertele kehamassiga > 40-60 kg
English: 250 tablets 30 tablets
Estonian: 250 tabletti 30 tabletti
English: (Invented) name
Estonian: (Väljamõeldud) Nimetus
English: Tablet Tablet
Estonian: Tablett Tablett
English: Oral use Oral use bottle (HDPE) blister (alu/alu)
Estonian: Suukaudne Suukaudne tabletipurk (HDPE) blister (alu/alu)
English: • Need to ensure appropriate hydration of the patient
Estonian: • Vajadus tagada patsiendi piisav hüdreeritus
English: • Need to measure serum creatinine before treatment with Zoledronic acid Teva Pharma
Estonian: • Vajadus mõõta vereseerumi kreatiniinisisaldust enne Zoledronic acid Teva Pharma'ga ravi alustamist
English: The MAH must agree the content and format of the educational material, together with a communication plan, with the national competent authorities in Member States prior to distribution of the educational programme.
Estonian: Enne retsepti kirjutaja juhendi levitamist igas liikmesriigis peab müügiloa hoidja kooskõlastama riikliku pädeva asutusega koolitusmaterjalide sisu ja vormi koos kommunikatsiooniplaaniga.
English: o Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non-smoking and healthy diet o Key signs and symptoms of serious adverse events o When to seek attention from the health care provider
Estonian: • Patsiendi infopakett peaks olema arstile antud ja sisaldama järgmist olulist informatsiooni: o Vajalik on piisav kaltsiumi ja D-vitamiini tarbimine, piisav füüsiline aktiivsus, mittesuitsetamine ja tervislik toitumine o Tõsiste kõrvaltoimete põhilised tunnused ja sümptomid o Millal pöörduda arsti poole
English: • One-yearly dosing regime
Estonian: • Üks kord aastas annustamisreziim
English: • Contraindication in pregnancy and in breast-feeding women • Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non
Estonian: • Vajalik on piisav kaltsiumi ja D-vitamiini tarbimine, piisav füüsiline aktiivsus, mittesuitsetamine ja tervislik toitumine
English: What measures are being taken to ensure the safe and effective use of Orencia?
Estonian: Mis meetmed võetakse, et tagada Orencia ohutu ja efektiivne kasutamine?
English: Further information on Orencia can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/orencia.
Estonian: Lisateave Orencia kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/orencia.
English: Orencia received a marketing authorisation valid throughout the EU on 21 May 2007.
Estonian: Orencia on saanud müügiloa, mis kehtib kogu ELis, 21. mail 2007.
English: Orencia (abatacept)
Estonian: Orencia (abatatsept)
English: Other information about Orencia
Estonian: Muu teave Orencia kohta
English: Around three-quarters of the patients were also taking methotrexate.
Estonian: Patsientidest ligikaudu kolmveerand võtsid ka metotreksaati.
English: As for all medicines, data on the use of Orencia is continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Orencia kasutamise kohta pidevat järelevalvet.
English: What is Orencia and what is it used for?
Estonian: Mis on Orencia ja milleks seda kasutatakse?
English: If Orencia has not worked within 6 months, the doctor should consider if treatment should continue.
Estonian: Kui Orenciaga ei teki 6 kuu jooksul ravivastust, peab arst kaaluma, kas jätkata ravi või mitte.
English: The Agency decided that Orencia's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Orencia kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Patients who receive Orencia are given a special alert card explaining that it must not be used in patients with certain infections and instructing patients to contact their doctor immediately if they develop an infection during treatment with Orencia.
Estonian: Orenciat saavatele patsientidele antakse hoiatuskaart, kus selgitatakse, et ravimit ei tohi kasutada teatavate infektsioonidega patsiendid, ning soovitatakse patsientidel otsekohe arsti poole pöörduda, kui neil tekib Orencia kasutamise ajal infektsioon.
English: The main measure of effectiveness was a reduction in symptoms of at least 20% after 24 weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli vähemalt 20% sümptomite vähenemine pärast 24nädalast ravi.
English: After being trained and with the agreement of their doctor, patients or carers may inject the medicine themselves.
Estonian: Pärast väljaõppe saamist ja arsti loal võivad patsiendid või hooldajad ravimit ise süstida.
English: Children between 2 and 6 years should only use Orencia pre-filled syringes.
Estonian: 2-6aastased lapsed tohivad kasutada üksnes Orencia eeltäidetud pensüstlaid.
English: Side effects reported with Orencia are carefully evaluated and any necessary action taken to protect patients.
Estonian: Orencia kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: What are the risks associated with Orencia?
Estonian: Mis riskid Orenciaga kaasnevad?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Orencia have also been included in the summary of product characteristics and the package leaflet.
Estonian: Orencia ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The dose depends on the patient's weight.
Estonian: Annus sõltub patsiendi kehakaalust.
English: By attaching to signal molecules called CD80 and CD86, abatacept stops them activating the T cells, helping to reduce the inflammation and other symptoms of the diseases.
Estonian: Virgatsmolekulidele CD80 ja CD86 kinnitudes takistab abatatsept neid T-rakke aktiveerimast, aidates vähendada põletikku ja muid haigussümptomeid.
English: The main measure of effectiveness was how long it was before the patient's disease flared up again.
Estonian: Efektiivsuse põhinäitaja oli aeg patsiendi haiguse uue ägenemiseni.
English: Orencia is a medicine that is often used in combination with methotrexate (a medicine that acts on the immune system) to treat the following diseases:
Estonian: Orencia on ravim, mida kasutatakse sageli koos metotreksaadiga (immuunsüsteemi mõjutav ravim) järgmiste haiguste raviks:
English: The most common side effects with Orencia (seen in more than 1 patient in 10) are upper respiratory tract infections (nose and throat infection).
Estonian: Orencia kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on ülemiste hingamisteede infektsioonid (nina- ja kurgunakkused).
English: When given by infusion into a vein, Orencia is given every 2 weeks for the first 3 doses, and then every 4 weeks.
Estonian: Veeniinfusioonina manustatakse Orencia esimesed 3 annust iga 2 nädala järel ja seejärel iga 4 nädala järel.
English: • highly active and progressive rheumatoid arthritis, used in combination with methotrexate in adults who have not previously been treated with methotrexate;
Estonian: • väga aktiivne ja progresseeruv reumatoidartriit, koos metotreksaadiga täiskasvanutel, keda ei ole varem metotreksaadiga ravitud;
English: Subsequently, it is injected under the skin once a week.
Estonian: Pärast seda süstitakse ravimit naha alla üks kord nädalas.
English: For more information about using Orencia, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Orencia kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: How does Orencia work?
Estonian: Kuidas Orencia toimib?
English: When injected under the skin, Orencia is given once a week.
Estonian: Naha alla süstimisel manustatakse Orenciat üks kord nädalas.
English: In rheumatoid arthritis, if the patient is receiving Orencia for the first time, the first dose can be given by infusion.
Estonian: Kui reumatoidartriidiga patsient kasutab Orenciat esimest korda, võib esimese annuse manustada infusiooni teel.
English: Orencia must not be used in patients with severe and uncontrolled infections, such as sepsis (when bacteria and their toxins circulate in the blood and start to damage the organs) or ‘opportunistic' infections (infections seen in patients with a weakened immune system).
Estonian: Orenciat ei tohi kasutada patsiendid, kellel on rasked ja ohjamata infektsioonid, näiteks sepsis (bakterite ja toksiinide levik verre, mis kahjustab elundeid) või oportunistlikud infektsioonid (nõrgenenud immuunsüsteemiga patsientidel esinevad infektsioonid).
English: The European Medicines Agency concluded that Orencia had a modest anti-inflammatory effect in rheumatoid arthritis and, in combination with methotrexate, it reduced the worsening of joint damage and improved physical function.
Estonian: Euroopa Ravimiamet järeldas, et Orencial oli reumatoidartriidi ravis mõõdukas põletikuvastane toime ning et koos metotreksaadiga vähendas see liigesekahjustuse süvenemist ja parandas kehalist aktiivsust.
English: The study included 259 patients who had previously been treated with a TNF alpha blocker.
Estonian: Uuringus osales 259 patsienti, kes olid varem saanud ravi TNFα-blokaatoriga.
English: The study also led to similar improvements in symptoms to those seen with Orencia given into a vein in adults and children.
Estonian: Uuringus saavutati ka sarnane sümptomite paranemine nagu Orencia veeni manustamisel täiskasvanutel ja lastel.
English: The main measures of effectiveness were the reduction in symptoms of arthritis after treatment, as well as physical function (the ability to carry out everyday tasks) and the amount of damage to the joints (assessed using X-rays).
Estonian: Efektiivsuse põhinäitajad olid artriidisümptomite vähenemine ravi järel, samuti kehalise aktiivsuse (võime sooritada igapäevaseid toiminguid) ja liigesekahjustuste määr (hinnati röntgenülesvõtete alusel).
English: T cells are activated when signal molecules attach to receptors on the cells.
Estonian: T-rakud aktiveeruvad, kui virgatsmolekulid kinnituvad rakkudel paiknevatele retseptoritele.
English: In polyarticular juvenile idiopathic arthritis, Orencia infusion was found effective in one main study involving patients aged between 6 and 17 years whose previous treatment had not worked.
Estonian: Polüartikulaarse juveniilse idiopaatilise artriidi ravis tõendati Orencia infusiooni efektiivsust ühes põhiuuringus, milles osalesid 6-17aastased patsiendid, kellel varasem ravi ei toiminud.
English: Orencia was found effective in one main study involving 424 adult patients with psoriatic arthritis.
Estonian: Orencia efektiivsust tõendati ühes põhiuuringus, milles osales 424 psoriaatilise artriidiga täiskasvanut.
English: In the fourth study, Orencia in combination with methotrexate was compared with Orencia alone and methotrexate alone in 351 adults who had not been treated with methotrexate (or with any biologic agents such as TNF alpha blockers), but may have been on other medicines for management of rheumatoid arthritis.
Estonian: Neljandas uuringus võrreldi Orencia ja metotreksaadi kombinatsioonravi ning Orencia ja metotreksaadi monoteraapiat 351 täiskasvanul, keda ei olnud varem ravitud metotreksaadiga (või mis tahes bioloogiliste ravimite, nt TNFα-blokaatoritega), kuid kes võisid olla kasutanud reumatoidartriidi raviks muid ravimeid.
English: The Agency also concluded that Orencia could be a valuable option in the treatment of polyarticular juvenile idiopathic arthritis.
Estonian: Amet järeldas ka, et Orencia võib olla kasulik ravivalik polüartikulaarse juveniilse idiopaatilise artriidi ravis.
English: In around 60% of these patients the TNF alpha blocker had not worked well enough.
Estonian: Umbes 60% patsientidest ei olnud saavutanud TNFα-blokaatoriga piisavat ravivastust.
English: All patients received Orencia for 4 months, after which the 122 whose condition had improved on Orencia were either switched to placebo or continued receiving Orencia.
Estonian: Kõik patsiendid said Orenciat 4 kuu vältel ning pärast seda said 122 ravivastusega patsienti kas platseebot või jätkasid Orencia-ravi.
English: What benefits has Orencia have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Orencia kasulikkus?
English: How is Orencia used?
Estonian: Kuidas Orenciat kasutatakse?
English: T cells are immune system cells that are involved in causing the inflammation in rheumatoid, psoriatic and polyarticular juvenile idiopathic arthritis.
Estonian: T-rakud on immuunsüsteemi rakud, mis osalevad reumatoidartriidi, psoriaatilise artriidi ja polüartikulaarse juveniilse idiopaatilise artriidiga kaasneva põletiku põhjustamises.
English: In this case it should be followed by an injection under the skin the next day.
Estonian: Sellele järgneb järgmisel päeval nahaalune süste.
English: The first two studies included 991 patients in whom methotrexate had not worked well enough.
Estonian: Esimeses kahes uuringus osales 991 patsienti, kes ei olnud saavutanud metotreksaadiga piisavat ravivastust.
English: Orencia was also shown to reduce symptoms of psoriatic arthritis.
Estonian: Orencial on tõendatud psoriaatilise artriidi sümptomeid vähendav toime.
English: It is used in combination with methotrexate, or on its own in patients who cannot take methotrexate.
Estonian: Ravimit kasutatakse koos metotreksaadiga või ainsa ravimina patsientidel, kes ei saa metotreksaati võtta;
English: A further study in 219 children with polyarticular juvenile idiopathic arthritis aged 2 to 17 years showed that Orencia given by injection under the skin produced expected levels of active substance in the blood based on data with Orencia given into a vein for other conditions.
Estonian: Veel ühes 219 polüartikulaarse juveniilse idiopaatilise artriidiga 2-17aastasel lapsel tehtud uuringus saavutati Orencia naha alla süstimisel veres toimeaine sisaldus, mida võis eeldada muudel näidustustel Orencia veeni manustamisel saadud andmete põhjal.
English: Orencia contains the active substance abatacept.
Estonian: Orencia sisaldab toimeainena abatatsepti.
English: The active substance in Orencia, abatacept, is a protein that suppresses the activation of T cells.
Estonian: Orencia toimeaine abatatsept on valk, mis pärsib T-rakkude aktiveerimist.
English: In addition, a study involving around 1,370 patients with rheumatoid arthritis found similar benefit for both Orencia given by injection under the skin and Orencia given by infusion.
Estonian: Lisaks täheldati umbes 1370 reumatoidartriidiga patsiendi uuringus sarnast kasulikku toimet Orencia manustamisel nii nahaalusel süste kui ka infusioonina.
English: It is used alone or in combination with methotrexate for patients who do not need other medicines by mouth or by injection to control their psoriasis.
Estonian: Seda kasutatakse ainsa ravimina või koos metotreksaadiga patsientidel, kes ei vaja psoriaasi reguleerimiseks muid suukaudseid või süstitavaid ravimeid.
English: • psoriatic arthritis (arthritis combined with psoriasis, a condition causing red, scaly patches on the skin) in adults in whom treatment with other medicines, including methotrexate, has not worked well enough.
Estonian: • psoriaatiline artriit (artriit koos psoriaasiga - haigus, mis põhjustab punaseid ketendavaid nahalaike) täiskasvanutel, kellel muud ravimid, sealhulgas metotreksaat, ei ole piisavalt toiminud.
English: • moderate to severe active polyarticular juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints), in adolescents and children from 2 years of age in whom other medicines have not worked well enough.
Estonian: • mõõdukas kuni raske aktiivne polüartikulaarne juveniilne idiopaatiline artriit (paljudes liigestes põletikku põhjustav harv lapseea haigus) noorukitel ja vähemalt 2aastastel lastel, kellel muud ravimid ei ole piisavalt toiminud.
English: Patients taking Orencia also had a greater improvement in physical function after six months.
Estonian: Orenciat kasutanud patsientidel paranes 6kuulise ravi järel rohkem ka kehaline aktiivsus.
English: • moderate to severe active rheumatoid arthritis (an immune system disease causing damage and inflammation in the joints) in adults using it in combination with methotrexate when other medicines including methotrexate or a ‘tumour necrosis factor (TNF) blocker' have not worked well enough;
Estonian: • mõõdukas kuni raske aktiivne reumatoidartriit (liigesekahjustusi ja -põletikku põhjustav immuunsüsteemi haigus) täiskasvanutel, koos metotreksaadiga, kui muud ravimid (sh metotreksaat või kasvaja nekroositeguri (TNF) blokaator) ei ole piisavalt toiminud;
English: An overview of Orencia and why it is authorised in the EU
Estonian: Ülevaade ravimist Orencia ja ELis müügiloa väljastamise põhjendus
English: The second study found a similar effect of Orencia on symptoms of rheumatoid arthritis, as well as improved physical function and a reduced rate of joint damage after a year of treatment.
Estonian: Teine uuring tõendas Orencia samalaadset toimet reumatoidartriidi sümptomitele, samuti paranes üheaastase ravi järel patsientide kehaline aktiivsus ja vähenes liigesekahjustuste määr.
English: Orencia is available as a powder that is made up into a solution for infusion (drip) into a vein and as a solution for injection under the skin in pre-filled syringes and pre-filled pens.
Estonian: Orenciat turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina ning subkutaanse (naha alla süstitava) süstelahusena eeltäidetud süstaldes ja eeltäidetud pensüstaldes.
English: The third study included 391 patients in whom TNF blockers had not worked well enough.
Estonian: Kolmandas uuringus osales 391 patsienti, kes ei olnud saavutanud TNF-blokaatoritega piisavat ravivastust.
English: Orencia can only be obtained with a prescription, and treatment with it should be started and supervised by a specialised doctor with experience in the diagnosis and treatment of rheumatoid arthritis or polyarticular juvenile idiopathic arthritis.
Estonian: Orencia on retseptiravim ning ravi peab alustama ja jälgima reumatoidartriidi või polüartikulaarse juveniilse idiopaatilise artriidi diagnoosimises ja ravis kogenud eriarst.
English: In another study involving 170 patients with psoriatic arthritis, Orencia given by infusion at the recommended dose reduced symptoms by at least 20% after 24 weeks in over 47% of the patients (19 out of 40) compared with 19% of the patients (8 out of 42) who received placebo.
Estonian: Teises uuringus, milles osales 170 psoriaatilise artriidiga patsienti, vähendas soovitatavas annuses Orencia infusioon 24 nädala järel sümptomeid vähemalt 20% võrra enam kui 47%-l patsientidest (19 patsienti 40st); platseeborühmas saavutas sama tulemuse 19% patsientidest (8 patsienti 42st).
English: Adding Orencia and methotrexate to existing treatment for 12 months reduced symptoms in 61% of the patients (70 out of 115), compared with 42% of the patients on Orencia alone (48 out of 113) and 45% of the patients on methotrexate alone (52 out of 115).
Estonian: Orencia ja metotreksaadi lisamisel olemasolevale ravile 12 kuu jooksul vähenesid sümptomid 61%-l patsientidest (70 patsienti 115st), kusjuures ainult Orenciat saanud patsientidest vähenesid sümptomid 42%-l (48 patsienti 113st) ja ainult metotreksaati saanud patsientidest 45%-l (52 patsienti 115st).
English: Adding Orencia to existing treatment led to a reduction in symptoms in 50% of the patients (129 out of 256) after 6 months, compared with 20% of the patients adding placebo (26 out of 133).
Estonian: Orencia lisamisel olemasolevale ravile vähenesid sümptomid 6 kuu järel 50%-l patsientidest (129 patsienti 256st) ning platseebo lisamisel vähenesid sümptomid 20%-l patsientidest (26 patsienti 133st).
English: Orencia given by injection under the skin reduced symptoms in 39% of the patients (84 out of 213) compared with 22% of the patients (47 out of 211) who received placebo.
Estonian: Orencia nahaalusel süstimisel vähenesid sümptomid 39%-l patsientidest (84 patsienti 213st) ning platseeborühmas vähenesid sümptomid 22%-l patsientidest (47 patsienti 211st).
English: In the first study, symptoms of the disease were reduced in 61% (70 out of 115) of the patients adding the recommended dose of Orencia to methotrexate for 6 months, compared with 35% (42 out of 119) of the patients adding placebo (a dummy treatment).
Estonian: Esimeses uuringus vähenesid haigussümptomid 61%-l patsientidest (70 patsienti 115st), kelle metotreksaatravile lisati 6 kuuks Orencia soovitatav annus, ning 35%-l platseebot (näiv ravim) saanud patsientidest (42 patsienti 119st).
English: Over 6 months, 20% of the patients receiving Orencia had a flare-up (12 out of 60), compared with 53% of those receiving placebo (33 out of 62).
Estonian: 6 kuu jooksul oli ägenenud haigusega patsiente Orencia rühmas 20% (12 patsienti 60st) ja platseeborühmas 53% (33 patsienti 62st).
English: Four main studies involving a total of 1,733 adults found Orencia effective in rheumatoid arthritis.
Estonian: Orencia efektiivsust reumatoidartriidi ravis tõendati neljas põhiuuringus, milles osales kokku 1733 täiskasvanut.
English: 41% 32% Odds Ratio:
Estonian: 41% 32% Riskisuhe: